At 2023, I used Zoloft for 3 months and after tapering off, I had PSSD for 1.5 years. I still think my libido is not the same, although I reach orgasm very quickly now. I’m 24 and a woman. I’m battling with major depressive disorder yet again, and don’t want to lose a part of me all over, I love my libido, the joy I get from masturbating. I am human and living after all. It’s scary, I never even had sex yet.

My therapist says I must take medication at this point. Anything I can do to combat this illness without meds? I already eat well, do sports. Depression was induced by my dad‘s cancer and unemployment. It wasn’t due to malnutrition etc.

How do I get out of this pit without losing a part of me?

And I am so, so sorry for anybody else going through PSSD and depression, I know how heartbreaking it is for a “treatment” to take a part from you, I am so sorry.

If anyones looking to talk about their situation just message me 👍 need people to talk to who are in the same situation

I started SSRIs at 13, I was taking them for 1,5 year and since then I couldn't have a pleasurable orgasm (physically happens, but almost no sensation) or feel my tip. Recently I saw someone on here saying they lost their nipple sensation after SSRIs. I thought no one could feel their nipples, but turns out no. I can't feel any part being touched, the tip nor the circles around them, but in the tips I can feel cold if I press something cold to them. Anyone else on here got something similar?

Hi everyone, some help would be greatly appreciated, if any of you amazing people could spare some knowledge or information please. My younger sister has been suffering with PSSD for over 2 years. When I say suffering, I mean it’s absolutely ruined her life and shot down any dreams she’s ever had (as most of you already know). She is mostly bed bound and we don’t know how to help. I worry she’s losing hope of ever overcoming this. I understand that there is currently only one Dr or very few professionals looking into treatments and mechanisms of PSSD and I understand it’s so discouraging for any one of you or your loved ones going through this. What I want to do is reach out to as many professionals I can to raise awareness of PSSD and how it is affecting people’s lives and just at-least try to ignite some compassion and interest in the subject to hopefully spur on more research and funding.
If anyone could give me any information on Drs names, PSSD organisations, mental health drs or current research happening that links to PSSD. Even any information that you think that would help at all. I want to do this on behalf of my 27 year old sister as she is so fatigued and struggling to fight anymore.
I just wanted to say that I have a previous medical background so I am familiar with abbreviations, medical terms and research papers.
Thanks Everyone
Amy

The medication caused mild blurriness in my vision, light sensitivity, and an additional 0.5 diopter of astigmatism.Why am I so sure? Because both of my parents have prescriptions within minus 4.0 diopters. I tested at minus 4.0 in 2020, and by 2024, both eyes were nearly minus 6.0. In 2025, it barely changed, and yesterday's test showed no change either—except for an additional 0.5 diopter of astigmatism.

That means from 2016 to 2025, I spent about 15 hours a day staring at my phone and computer—using cheap, low-quality small screens, in the dark, often lying on my side for long periods. I also frequently ejaculated, which left my body weakened and likely worsened my myopia. But even with all that, I never developed astigmatism. And from 2024 to 2026, my prescription didn't change at all.

Then, starting last November, over the course of six months, I took a total of 16 tablets of paroxetine—only 1/4 tablet per day. During those six months, I felt my vision was a bit blurry, and I assumed my prescription had increased again. But yesterday I had a comprehensive eye exam—everything else was fine, except for the new 0.5 diopter of astigmatism.

It's now been three months since I stopped the medication. The emotional and cognitive numbness, along with the gastrointestinal constipation and bloating, have mostly recovered. Only the sexual dysfunction and the 0.5 diopter of astigmatism haven't improved at all. I've been exercising regularly since July 2025, and I'm physically in the best shape I've been in over the past 12 years. This sudden 0.5 diopter of astigmatism is definitely not natural.I don't know whether there's some underlying eye condition that medical tests can't pick up, but based on how I feel, I believe my vision is now about 2.00 diopters worse than it was before I started the medication last November.

I have had PSSD for a long time, and my recovery has been very slow. I have noticed some improvement, but the progress is extremely gradual. However, I am still taking 10 mg of Brintellix (vortioxetine) because if I stop taking it, my mental health deteriorates and I relapse.
Could continuing to take this medication slow down or interfere with my recovery from PSSD?

Hey people. I have been lurker at this subreddit for a while now without ever posting anything. However, im sort of desperate at the moment and I know how against people here against reinstatement in general. However, I do in fact believe most of us would go back on the drug [if they barely experienced side effects on the drugs] to be "well again".

Brief backstory. I was on zoloft for about 5-6 years until I decided to taper it off. First I did way too fast. As in like two weeks I stopped completely. Which i almost immediately experienced full emotional blutning and scariest part was probably complete genitals anesthetic feeling. I reinstated the drug like 2 weeks after and immediately after 30 mins my genitals completely resolved itself and emotional numbness subsidised.

Couple of months later I decided to do a "slower taper" which I did over a course of 6 months which i believe was still to damn fast. I didnt read about it anywhere so I did it from my logical standpoint.

I did experience all sort of symptoms during taper especially at lower dosages but most of the symptoms started at 0.

Symptoms: Burning brain, DPDR, vision issues, cognitive issues, weakness, no hunger, emotionally i was not so blunted but somewhat i could libe with it. It was mostly neurological symptoms. However, this time my sexual function remained and did sort of have libido. So I pushed through. I did fell mostly okay for 5 months then "True withdrawal" started. I got hit first by immense stomach fullness and i could barely eat. Erections started to be varied. [Im fully in the camp believing its related to the gut] since my erections started to be bad after stomach issues started. I thought okay this scary and might be temporary but I knew about pssd. At month 6 I had full blown ED, went into severe depression/anhedonic/severe anxiety to the point I almost called ER. I managed to hold out until month 7 until I decided to reinstate the drug. 2mg or so.

At first it increased my anxiety and gave me immense SI thoughts. Which i also experienced when I tried the drug for the first time. However, what i also noticed this time .. it nullified all other emotions expect anxiety. I took it for 5 days in total before I quit it again. Its been 3 weeks since and now im severely numb. Sexual function is somewhat intact. [No libido whatsoever but I do get erections]

So my biggest problem at the moment is severe emotional blunting, head pressure again, and bloated stomach again. No hunger again. Which I managed to regain after being 6 months off. All my internal signals are basically numbed out. I dont bother doing anything.

Question for you guys or perhaps mods. What would you do in my situation? Should I try to reinstate again with even lower dosage? Should I wait?

Hard to tell if its pssd or protracted withdrawal. Perhaps both. At the same time I do believe I gave my system a shock in sensitive state and it turned off everything basically.

I’m interested in finding a recommended private doctor/psychiatrist who is willing to prescribe medications off label e.g Bupropian, Pramipexole. Any help would be appreciated. Thanks

MODSSSSSS. Cmon before the shitty PFSN steals it.

I guess this could be a dumb question, like maybe if the answer was known then the problem of PSSD could be solved. But what are the theories about why nipples and genitals go numb? My nips are like 100% numb whereas my genitals are like 75% numb. Nips still get hard when I’m cold or when I sneeze or when touched, but I can’t feel them AT ALL. WHYYYY

Most of my symptoms have got better except sexual one. And it got worse when I tried Agnus Castus 30ch one dose. I took khali phos it improves my condition. First it improved my brain fog, then irritation, tinnitus. It gives me morning erection and minutely improves my libido.

Hi everyone,

When I started taking escitalopram and developed PSSD from it i took Vitamin C complex with BioPerine in it and i read that it can inhibit CYP2D6 and other enzymes for 6-12 hours strongly.
I’ve been thinking about potential triggers that might cause PSSD or contribute to its most severe forms, and I wanted to run a quick survey/discussion on a specific pharmacological interaction: BioPerine (Piperine / Black Pepper Extract).
The Hypothesis:
BioPerine is widely added to supplements (like Curcumin/Turmeric, Zinc, Multivitamins, or fat burners) to enhance bioavailability. It does this by strongly inhibiting CYP3A4 and CYP2D6 enzymes in the liver, as well as P-glycoprotein (P-gp) at the blood-brain barrier.
Since most SSRIs (like Fluoxetine, Paroxetine, Sertraline, Escitalopram etc.) are metabolized by these exact same CYP enzymes, combining them with BioPerine can cause a sudden, massive spike in SSRI blood plasma levels. Furthermore, inhibiting P-gp allows the medication to penetrate the central nervous system much more aggressively. This could theoretically lead to severe receptor overload or drastic desensitization, potentially triggering PSSD or worsening its severity.
Please check your past/current supplements (even standard multivitamins) and let me know:
1. Did you take BioPerine / Piperine / Black Pepper Extract while on SSRIs, or during the withdrawal/tapering phase? (It is often hidden in Curcumin, CoQ10, Vitamin C complex or high-end vitamin complexes).
2. If yes, what kind of PSSD symptoms do you experience? (e.g., severe form with complete emotional/physical numbness, anhedonia, or milder/fluctuating symptoms?)
3. Did you notice your symptoms starting or significantly worsening around the time you took these supplements?
If you didn't take any supplements with black pepper extract, please feel free to comment "No" as well, so we can get a realistic picture of the ratio.

The question I keep coming back to is:

What brain function is intentionally shifted by chronic serotonin treatment in order to make a person less internally reactive, and what happens if that shift does not fully reverse?

What keeps standing out to me is that the symptoms of PSSD are usually described as if they belong to completely separate categories.

Sexual dysfunction.

Cognitive problems.

Word retrieval.

Emotional changes.

Facial expression.

But the more I look at the sequence of what happens in each of these systems, the more I start wondering whether the symptoms are actually different expressions of the same initial disruption.

Not the same symptom.

The same starting point in the cascade.

The sexual example is probably the easiest one for me to see.

Before antidepressants, a sexual stimulus could automatically generate a sexual state, which then maintained itself and recruited motivation and physical responses.

Now, the stimulus can still be registered. I can cognitively understand what I am seeing. But the state often does not spontaneously develop and carry itself forward.

I have to actively try to generate it.

And when I started looking at my cognition, I realised I was describing something strangely similar.

A thought can be initiated, but lose its trajectory.
I can know what I want to express, but lose the meaning or internal reference supporting it while trying to verbalise it.

Sometimes I genuinely cannot retrieve a word.
Sometimes the thought itself seems to lose its structure, and then the word becomes difficult to retrieve as well.

The more I thought about this, the more I started noticing the same pattern in other areas.

I am not necessarily unable to register the initial stimulus.

I am not necessarily unable to consciously understand what is happening.

The problem seems to occur after the initial registration.

Something is supposed to develop.

It is supposed to maintain itself.

It is supposed to recruit the next process.

And that is where things seem to break down.

This is why I am starting to question whether the sexual, cognitive and emotional symptoms are truly separate at the level of the underlying mechanism.

Because perhaps the important part is not what the symptom looks like at the end.

Perhaps the important part is where the cascade stops propagating.

A sexual stimulus is registered, but the sexual state does not naturally sustain itself.

A thought is initiated, but its trajectory can disappear.

A thought can exist, but lose the internal reference that would allow it to be expressed fluently.

An internal state may exist, but fail to recruit the same bodily or behavioural expression.

And this is also why I keep thinking about my facial expression.

Before antidepressants, my face seemed to follow my internal state automatically. I did not have to consciously manage my facial muscles or think about whether my expression matched what I was feeling.

Afterwards, I became much more aware of my facial muscles and my face felt less naturally expressive.
I am not saying that these are all necessarily caused by one single molecular abnormality.

But I am starting to wonder whether they could all be downstream expressions of a disruption in the same basic functional process:

the spontaneous maintenance and propagation of an internally generated state.

Because the more I look at it, the more it feels like the problem is not simply that I have less sexuality, less cognition or less emotion.

It is that the brain seems to have more difficulty taking something that has been initiated and allowing it to naturally develop into the next state.
And if that is true, then the question becomes much more interesting to me.

What biological system is responsible for allowing an internally generated state to maintain itself and propagate across different systems, from thought, to motivation, to emotion, to autonomic and bodily responses?

Because if the initial disruption is the same, then perhaps PSSD is not primarily a collection of separate sexual, cognitive and emotional symptoms.
Perhaps it is one disrupted process expressing itself differently depending on which system the cascade was supposed to reach

(More in the comments)

I was prescribed Trazadone to fix pssd. Any opinions?

back under a new account, my old account was throwaway with a bunch of numbers and id previously posted about wellbutrin, proviron, caber, etc. got a new device and have no idea what the password is lol

will keep it short, i (21m) am currently taking wellbutrin 150 mg daily, tadalafil as needed (20-30mg, often w another 10mg after having sex) and have been able to relatively manage pssd symptoms the last few years, in the sense i’ve been able to have both long term relationships and casual hookups and have remedied my symptoms well enough that my partners wouldn’t guess anything’s off

anyways, i’ve been administering 250mcg of kisspeptin subcutaneously daily for a little under a week and have noticed an improvement in libido and EQ and a relief in HF-like symptoms that I experience. hooked up with someone 3 days into my cycle and it went well, which was a good sign as i’d taken less tadalafil than normal to experiment.

not really expecting long term success with this, as everything i’ve tried beyond wellbutrin and tadalafil eventually seem to wear off in efficacy, but i’ll keep taking it/figure out a cycle and report back at some point. it definitely is not a cure per se, but its been a good supplementary substance so far. still very early to report on it, and i know people have had varying results with the peptide but just thought id share my experience so far

Did it happen to anyone here that they have developed persistent emotional flatness / anhedonia after very short treatment, like only low dose treatment for a few days?

And if that happened, did you get sexual dysfunction also?

I have been trying to understand my experience of PSSD by looking at the sequence in which the changes actually happened, rather than assuming that every symptom appeared at the same time or came from the same mechanism.

The most important distinction in my case is that the primary change did not initially feel like cognitive decline, memory loss or “brain fog.”

The first thing I noticed during antidepressant treatment was the disappearance of my spontaneous internal mental activity.

Before antidepressants, my mind was constantly generating and connecting things. Thoughts naturally led to other thoughts. Feelings, bodily sensations, memories and ideas seemed to influence one another continuously. I was extremely self-aware and naturally introspective. I would analyse myself without consciously deciding to do so. My thoughts seemed to have a kind of internal momentum.

My brain used to internally connect things.

That was not simply “thinking a lot.” It was more like an ongoing internal process in which one thought generated another, one feeling changed my physical state, and that physical state could in turn influence my thoughts and emotions.

During antidepressant treatment, this seemed to disappear.

However, I did not initially experience it as a loss.

I felt lighter.

The negative thoughts that previously made me anxious, sad or distressed became much quieter. I experienced what felt almost like an automatic lift. I did not go through a period in which I felt dramatically worse before improving. In many ways, I felt better almost immediately.

But, retrospectively, I think something much more fundamental may have changed.

I was there, biologically, but it felt almost as if I was not there at all.

I was in what I can only describe as a vegetative or automatic state. Not necessarily constantly sad. Not necessarily consciously unhappy.

I was numb.

When people talked to me about their problems, I remember thinking that things were simply much more straightforward. I would think: “It’s not that complicated.” I did not seem to naturally generate the same layers of thought, emotional interpretation, empathy and internal associations that I had before.

At the time, however, I did not fully recognise what was happening.

This is important because I was previously an extremely self-aware and self-analytical person. I now wonder whether the reduction in spontaneous internal mentation also reduced my ability to observe and recognise the changes occurring within myself.

In other words:

I may have lost part of the internal process that would have allowed me to notice that I was losing it.

This is why I do not think my experience can be adequately described simply as “emotional blunting.”

I was not necessarily sitting there thinking “I feel numb.”

The internal observer that would have naturally examined that change also seemed diminished.

The change became much more obvious to me after I stopped taking antidepressants, particularly after I reconnected with someone who had known me before treatment.

He told me that I was completely different. He described me as having previously been much “colder.” This was particularly striking to me because I remembered myself as someone who was emotionally intense and deeply affected by things. I had always been a very emotional person, but I also had an internal structure that seemed to force me to analyse, contain and give meaning to what I felt.

I was not “cold” because I felt nothing.

I think I was emotionally intense but internally structured.

My feelings had weight. They had meaning. I could become deeply distressed by what other people were experiencing because I could not simply ignore or mentally filter out the things other people were feeling. I would imagine their experience, emotionally register it and be affected by it.

After antidepressants, something about that internal process seemed to disappear.

When I reconnected with this person, I remember feeling different around him. I remembered, at least partially, how I had felt before. I remembered how deeply I had loved him and how significant he had been to me.

And this was one of the moments that made me stop and think:

“Wait. What happened to me?”

It was almost as if I had been in autopilot the entire time.

There was nobody inside.

This is also where I think I need to distinguish between emotional reactivity and affective or sentimental meaning.

Today, I may talk about something and feel emotional, want to cry, or have a strong bodily reaction.

But before, I think I was much more connected to what the experience meant to me.

I could focus on the feeling itself, on its significance, on what the person or experience represented internally.

Now I often feel that the emotional reaction exists more independently from the deeper meaning.

I can feel emotional without feeling the same depth of sentiment.

This may be why I sometimes describe myself as having become more emotional but less sentimental.

The primary change, therefore, does not seem to me to have been a simple loss of intelligence or even a simple loss of emotion.

It felt like the disappearance of the internal generative system that previously produced thoughts, connected them to one another, generated emotional meaning and allowed me to continuously observe myself.

I later began noticing much more obvious cognitive and linguistic problems: difficulty retrieving words, a reduced vocabulary compared to before, losing the structure and meaning of what I am saying, grammatical errors I would previously have detected automatically, incorrect conjugations, mismatches between singular and plural, stopping sentences halfway and struggling to maintain a coherent train of thought.

However, these were not the first changes I noticed.

During treatment, I could still speak relatively fluently.

The first thing that disappeared was the internal world.

Only later did I begin to realise:

“Wait. I can barely speak.”

This is why I currently wonder whether the cognitive and linguistic symptoms should automatically be considered the primary phenomenon.

My current hypothesis is that a profound alteration in spontaneous internally generated mental activity may have occurred first, during treatment.

The initial reduction in negative thought and emotional distress may have been experienced as therapeutic relief. However, the same broader alteration may have affected the spontaneous generation and integration of internal thought, affective meaning, self-awareness and interoceptive experience.

After discontinuation, I experienced a marked shift towards much greater anxiety, agitation and internal hyperarousal. I do not necessarily think this state caused the original alteration. I wonder whether it may instead have interacted with, amplified or made the consequences of the earlier change much more visible.

My experience therefore feels less like:

“The antidepressant made me emotionally numb.”

and more like:

“The antidepressant may have altered the internal process through which thoughts, emotions, bodily states and meaning were spontaneously generated and connected.”

The DMN and other large-scale brain networks may be relevant to this, but I no longer see “DMN undershoot” as the theory itself.

The phenotype I am actually trying to describe is the loss of spontaneous internal mentation and the loss of the internal continuity that previously made thought, emotion and interpersonal experience feel naturally connected.

My brain can still think.

I can still analyse.

I can still, sometimes, reconstruct things deliberately.

But I no longer naturally enter the same internal states or move between thoughts in the same way.

And the most important distinction in my experience is that my deliberate cognitive abilities appear to have partially recovered over time, while the spontaneous internal system that generated and connected my thoughts, feelings and sense of meaning has never fully returned.

I do not feel like I simply became less intelligent.

I feel like the internal process that made me feel like myself became quiet first, and only later did I begin to understand the cognitive consequences of that loss.

Edit:
Before, anxiety could come from anticipation, but it could also seemingly appear out of nowhere as a very strong, pre-verbal feeling of “something is wrong” or “I need to go home.” I had these intense internal states as a child and throughout my life. I don’t really experience that same kind of spontaneous affective state anymore.

I notice something similar with positive experiences. I can still cognitively recognise that something is interesting, beautiful or meaningful, and I can understand the significance of an idea or connection. The problem is that I don’t seem to register it through feeling in the same way anymore. I can understand that something is important, but the emotional experience of that importance isn’t really there.

So I wonder if what I am describing is not simply a loss of thoughts or emotions, but a loss of spontaneous affective salience, the internal process that used to give thoughts, experiences and things around me their emotional weight.

This may also be why I keep describing my mind as “quiet.” It is not just that there are fewer thoughts. There seems to be less happening internally that spontaneously generates the next thought, feeling or state.

Hi, I've been suffering from PSSD for the past four years. Has anyone noticed any connection between PSSD and pudendal neuropathy (or pudendal nerve neuropathy)? I had a pudendal nerve conduction study shortly after taking venlafaxine, and it showed a significantly prolonged latency.

Welcome to the Weekly Open Discussion thread! This is your place to ask quick questions, post memes, or leave one-sentence comments that might be too short for their own posts.

Please follow the subreddit rules when participating in this thread. For posts related to suicidal thoughts or if you need emotional support, please use the Monthly support Requested and Venting, Thread.

​

​The chronic syndromes triggered by SSRIs, finasteride, represent an acquired spectrum of peripheral and autonomic nerve damage, initiated by systemic mitochondrial toxicity. The primary targets are heavily energy‑dependent neuronal structures: dorsal root ganglia (DRG), unmyelinated C-fibers, autonomic ganglia, and cranial nerve nuclei.

​This condition ranges from length-dependent small fiber neuropathy (SFN) to widespread sensory-autonomic ganglionopathy. The peripheral deafferentation fundamentally deprives the central nervous system of normal sensory input. This triggers a secondary central component: a functional, reversible, AMPK-mediated metabolic blockade of the somatosensory cortex and its extensive networks. This unified framework accounts for the entire spectrum of symptoms—sensory loss, anhedonia, autonomic instability, and the collapse of the embodied self.

​1. The Mitochondrial Trigger and Axonal Transport Halt

​The unifying mechanism across these disparate drug classes is a catastrophic collapse in mitochondrial bioenergetics, driven by a gene-environment "two-hit" mechanism.

​First Hit (Genetic Vulnerability): Emerging genomic analysis in post-drug syndrome cohorts points to polymorphisms in the ATP5F1B gene, which encodes the catalytic beta subunit of mitochondrial F_1F_O ATP synthase (Complex V). Individuals with these variants possess a baseline inefficiency in final-stage ATP production. Under normal physiological conditions, this remains asymptomatic. Simultaneously, a primary bottleneck exists in genetic polymorphisms within the SLC22 gene family (specifically the Organic Cation/Anion Transporters: OATs/OCTs). These proteins act as the cellular "efflux pumps" responsible for shuttling xenobiotics, neurotransmitter metabolites, and hormonal byproducts out of the cytoplasm and into the extracellular space. Individuals with these polymorphisms possess a reduced capacity for cellular detoxification. Under baseline conditions, this is compensated for by redundant transport pathways. However, when a pharmaceutical agent (e.g., an SSRI ) is introduced, these compromised SLC22 transporters fail to clear the drug and its reactive metabolites from the intracellular environment. This leads to a pathological intracellular accumulation of the toxic agent.

​Second Hit (Toxigenic Trigger): In vitro and clinical studies demonstrate that the implicated drugs inflict direct, catastrophic damage on the mitochondrial respiratory chain and its lipid environment. For SSRIs (like escitalopram) and fluoroquinolones, evidence shows direct inhibition of Complex I or direct damage to mitochondrial DNA.

​Crucially, finasteride exerts an equally devastating bioenergetic blow through dual mechanisms. First, clinical tissue analyses reveal that finasteride degrades the NDUFS3 subunit, leading to the severe structural and functional compromise of Complex I. Second, pioneering pre-clinical research (e.g., Melcangi et al.) demonstrates that finasteride-induced 5-alpha-reductase inhibition completely collapses the synthesis of neuroactive steroids, particularly allopregnanolone. Because allopregnanolone is synthesized at the outer mitochondrial membrane (via the TSPO protein) and is critical for maintaining the mitochondrial membrane potential (\Delta\Psi_m), its profound depletion strips the mitochondria of essential neuroprotection, leaving them highly vulnerable to unbuffered oxidative stress.

​When this multi-pronged toxic assault—direct Complex I blockade (via NDUFS3 degradation or SSRI inhibition) and the loss of steroidal membrane protection—meets a genetically compromised F_1F_O ATP synthase (ATP5F1B), the cell's reserve energy capacity definitively collapses. This profound ATP deficit immediately halts highly energy-demanding cellular processes. Unmyelinated C‑fibers and large DRG neurons are exceptionally vulnerable. The energy crisis acutely arrests axonal transport in these long fibers, initiating distal degeneration (in length-dependent SFN) or structural neuronal apoptosis (in widespread ganglionopathy).

​2. Receptor Sorting: The SNARE Transport Mechanism

​The mitochondrial energy crisis explains the highly specific sensory deficits observed in patients, particularly the dissociation in thermal/chemical sensitivity:

​The delivery of TRPV1 (heat/pain) and TRPA1 channels to peripheral nerve endings relies on highly energy-dependent, SNARE-mediated vesicular transport. Under ATP depletion, this transport fails, explaining the delayed or entirely absent sensory reaction to topical capsaicin.

​Conversely, TRPM8 channels (cold receptors) are significantly less metabolically demanding to transport. This directly correlates with the clinical presentation where patients retain a normal sensory response to menthol or cold, despite profound heat and pain insensitivity.

​3. Demyelination and the Cuprizone Parallel

​Mitochondrial dysfunction and oxidative stress severely impair Schwann cells. This parallels the classic Cuprizone experimental model, where mitochondrial failure induces widespread demyelination. Supporting this mechanism, MRI findings in at least one PSSD patient have revealed distinct foci of demyelination.

​Clinically, this structural compromise manifests as Uhthoff’s phenomenon. When body temperature rises, these demyelinated, metabolically compromised axons completely fail to conduct action potentials, causing a temporary, severe exacerbation of neurological and sensory symptoms upon heat exposure.

​4. Cortical Hibernation: AMPK-Mediated Metabolic Depression

​A crucial feature of this syndrome is the specific chronological sequence: peripheral sensory loss (e.g., genital numbness) precedes central emotional flattening.

​When massive peripheral denervation occurs, the somatosensory cortex is deprived of its tonic afferent input. Instead of undergoing structural destruction immediately, the cortex enters a functional, potentially reversible state of AMPK-mediated metabolic depression. Because the somatosensory cortex shares extensive networks with the insula, anterior cingulate cortex (ACC), prefrontal valuation centers, hypothalamus, and autonomic brainstem nuclei, this localized hibernation cascades into systemic symptoms.

​Clinical Parallels and Proof of Denervation:

​Spinal Cord Injury (SCI): Patients with high spinal cord injuries—who experience pure physical deafferentation without primary brain chemical imbalances—demonstrate a qualitatively identical clinical picture of emotional flattening, anhedonia, and depersonalization.

​Sensory Deprivation: Experimental sensory deprivation reliably induces similar cognitive and personality disruptions.

​Cortical Remodeling: Patients frequently report referred sensations and utilize "sensory tricks" (geste antagoniste). These phenomena are classic neurological hallmarks of cortical map reorganization, serving as definitive proof that actual peripheral denervation has occurred.

​5. The Deafferentation Paradigm and Dopaminergic Injury (COVID-19 and Beyond)

​This precise mechanism is heavily corroborated by large-scale serial neuroimaging studies. Landmark data from the UK Biobank database alongside updated imaging studies through 2026 have definitively mapped structural brain damage in patients experiencing chronic sensory loss. These studies revealed significant, accelerated loss of gray matter thickness and tissue damage in the orbitofrontal cortex and parahippocampal gyrus. Crucially, researchers established that this cortical damage was not primarily driven by direct viral neuroinvasion, but was a direct consequence of sensory deafferentation caused by peripheral damage to olfactory pathways (anosmia). The prolonged absence of incoming signals caused the corresponding brain cortices to literally wither and structurally degrade from disuse.

​Adding a critical layer to this central pathology, a 2026 neuroimaging study published in eBioMedicine by the Center for Addiction and Mental Health (CAMH) provides the strongest evidence to date that these post-viral states are associated with direct injury to dopamine-releasing neurons in the brain [1]. When applied to the post-drug model, this indicates that the initial deafferentation and metabolic crisis do not solely drive cortical gray matter atrophy, but actively damage or functionally downregulate the midbrain dopaminergic reward system. This specific dopamine system injury serves as a concrete structural explanation for the profound lack of motivation, deep anhedonia, and emotional flattening that solidify in the chronic phases of these syndromes.

​6. Direct Application to Post-Drug Progressions

​This principle directly scales to the slowly progressive timeline observed in PSSD, PFS,

​Insular and Somatosensory Atrophy: The acute loss of genital sensation, the destruction of C-tactile afferents (which process rewarding touch), and autonomic blunting starve the somatosensory and posterior insular cortices of vital afferent nourishment.

​The Progressing Symptom Profile: In the first months, profound anhedonia and a nonexistent libido stem from functional, high-threshold metabolic inhibition (hibernation). However, as months turn into years without peripheral signal restoration, transneuronal degeneration takes over. The brain physically prunes and downregulates the neural hardware in the somatosensory-insular-limbic axis. This structural decay explains why the anhedonia, loss of deep emotional resonance, and asexuality feel increasingly locked-in and progressive over time.

​7. Therapeutic Horizons: Neuroplasticity and Reversibility

​Understanding that the late-stage central symptoms involve structural transneuronal degeneration transitions our therapeutic goal: we must move beyond simple anti-inflammatory or endocrine strategies and focus on forced cortical excitability and structural neuroplasticity to reverse gray matter loss.

​Targeted Neuromodulation: Artificially forcing cortical excitability using electromagnetic fields can lower the perceptual threshold of the somatosensory cortex, forcing it out of AMPK-mediated hibernation to actively process the residual, subthreshold peripheral signals that survive.

​Upregulation of Neurotrophic Factors: Reversing structural transneuronal atrophy requires rebuilding synaptic density (synaptogenesis). Interventions must aggressively target the upregulation of Brain-Derived Neurotrophic Factor (BDNF) and Glial Cell-Line Derived Neurotrophic Factor (GDNF) to reopen critical windows of structural remodeling.

​Forced Sensory Afferent Rehabilitation: Mirroring protocols used in stroke and phantom limb therapies, intensive, focused sensory pathways stimulation (via high-frequency electrical nerve stimulation or targeted sensory retraining) can act as an external "signal pump," sending artificial currents to the starved cortices to arrest the atrophy process and stimulate neuroplastic regrowth.

​8. Clinical Validation via Targeted rTMS

​The hypothesis that central symptoms are driven by a central cortical network block that eventually alters structure is clinically validated by targeted repetitive Transcranial Magnetic Stimulation (rTMS).

​Motor Cortex Stimulation: Targeted rTMS applied to the motor cortex yielded an instant, lateralized, and objectively registered reduction in tremor, directly witnessed and verified by a neurologist.

​Somatosensory Associative Cortex Stimulation: Applying high-frequency rTMS to the somatosensory associative cortex resulted in a pan-symptomatic improvement encompassing motor, sensory, emotional, autonomic, and sexual functions. This profound reversal has now been successfully reproduced in a second patient.

​While rTMS is not yet a realiable cure—the effect is temporary and requires regular maintenance sessions—it provides the first reproducible, mechanistically sound management strategy. By artificially overriding the central metabolic depression and forcing cortical excitability, rTMS lowers the perceptual threshold, allowing the brain to process residual peripheral signals and re-engage with remaining peripheral pathways, potentially halting transneuronal decay through forced use.

​9. Systemic Autonomic and Endocrine Consequences

​The spread of the pathology to autonomic ganglia explains the severe systemic symptoms:

​Cardiac and Autonomic Neuropathy: Absent heartbeat sensation, anhidrosis, and fluctuating tinnitus point to widespread cranial and autonomic denervation.

​Renin–Aldosterone System: Denervation causes baroreflex failure and hypersensitivity of renal \beta_1-receptors, resulting in elevated renin and aldosterone in the upright posture.

​Hypercortisolemia and Tissue Atrophy: Autonomic dysregulation of the HPA axis leads to sustained hypercortisolism. Combined with the loss of trophic peptides (CGRP, substance P) from degenerated C-fibers, this severely suppresses dermal collagen synthesis, resulting in skin atrophy and the spontaneous formation of striae.

​10. Current Gaps and Research Directions

​While this model comprehensively unifies the symptomatology, several critical gaps remain requiring further investigation:

​In Vivo Bioenergetic Evidence: There is currently a lack of direct, in vivo proof of severe mitochondrial damage occurring at standard clinical doses of escitalopram or finasteride in human tissues.

​Large-Scale Genomic Mapping: While early genomic data heavily implicates ATP5F1B (Complex V) and SLC22 transporter polymorphisms as the primary genetic bottlenecks, larger-scale genome-wide association studies (GWAS) are required to map the exact mutational landscape. Furthermore, the role of specific cytochrome P450 (CYP) polymorphisms in exacerbating intracellular drug accumulation requires deeper exploration alongside these mitochondrial variables.

​Neuroimaging of Cortical Volume: Systematic, longitudinal structural MRI protocols (Voxel-Based Morphometry) are urgently needed in post-drug cohorts to objectify the suspected gray matter loss and transneuronal degeneration in the somatosensory and insular cortices, utilizing the COVID-19 deafferentation studies as a structural roadmap.

​Neuroinflammation: The secondary role of neuroinflammation, specifically chronic microglial activation following neuronal injury, requires deeper exploration.

​Sample Size: The rTMS clinical validation currently relies on a very small sample size (N=2), necessitating independent, larger-scale replication.

​Institutional Recognition: The syndrome remains absent from official diagnostic manuals (ICD, DSM). This is an institutional barrier, rather than a scientific one, which severely hinders funding and large-scale clinical trials.

​11. Conclusion

​The Acquired Mitochondrial Neuropathy/Ganglionopathy hypothesis provides a definitive, logical cascade that demystifies the vast array of post-drug symptoms. By explicitly integrating the SLC22-mediated intracellular toxic accumulation (the upstream genetic trigger) with the ATP5F1B-linked mitochondrial bioenergetic collapse (the downstream executioner), this "Two-Hit" model moves the paradigm decisively away from elusive neurotransmitter imbalances.

​It establishes a demonstrable axis of pathology: a localized cellular detox failure initiates a profound energy crisis, which specifically arrests high-demand axonal transport. The subsequent peripheral deafferentation fundamentally disconnects the brain from the body, forcing the somatosensory networks into a state of AMPK-mediated cortical hibernation. Left unmitigated, this lack of constant sensory signaling causes the cortex to undergo structural transneuronal degeneration, directly driving the slowly progressive nature of the anhedonia and missing libido. This cascade entirely accounts for the severe clinical manifestations—from highly specific temperature/pain sensory dissociation to profound anhedonia, autonomic instability, and the collapse of the embodied self.

​Crucially, this framework is actionable. It aligns genetic vulnerability mapping with targeted clinical interventions, introducing targeted rTMS and neuroplasticity therapies as a mechanistically justified strategy to temporarily override central metabolic depression and restore central emotional, structural, and autonomic integrity. By bridging transporter genetics (SLC22) with neuro-metabolic neurology (Complex V and AMPK), we finally have a coherent roadmap that targets the actual structural and energetic failures driving these syndromes.

​Key References

​Emmerzaal, T. L., et al. (2021). Effect of antidepressants on mitochondrial function in vitro. Translational Psychiatry.

​Ľupták, M., et al. (2023). Escitalopram directly targets mitochondrial respiratory chain complex I. Biomedicine & Pharmacotherapy.

​Finsterer, J., & Segall, L. (2010). Drugs interfering with mitochondrial disorders. Drug and Chemical Toxicology.

​Sghirlanzoni, A., et al. (2005). Sensory neuronopathies. The Lancet Neurology.

​Frohman, T. C., et al. (2013). Uhthoff's phenomena in MS. Nature Reviews Neurology.

​Orefice, L. L., et al. (2016). Somatosensory Neurons and Social Behavior. Cell.

​Vrontou, S., et al. (2013). Making sense of touch: C-tactile afferents and the rewarding value of touch. Nature.

​Tzavara, E. T., et al. (2006). Endocannabinoids activate TRPV1 receptors to reduce spontaneous locomotor activity. Journal of Neuroscience.

​Pons, T. P., et al. (1991). Massive cortical reorganization after sensory deafferentation. Science.

​Douaud, G., et al. (2022). SARS-CoV-2 is associated with changes in brain structure in the UK Biobank. Nature.

​Makin, T. R., et al. (2013). Cortical reorganization after amputation. Brain.

​Nakane, S., et al. (2018). Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis. PMC10889307.

​[1] CAMH (2026). New study provides first evidence of dopamine system injury in the brain of long COVID patients. eBioMedicine (via MedicalXpress).

Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain - PubMed

https://pubmed.ncbi.nlm.nih.gov/39004950/

I recently came across a 2026 Nature Communications study titled “Early-Stage Corticostriatal Hyperactivity Impairs Cognitive Flexibility Alongside Striatal Cholinergic Dysfunction in an Alzheimer’s Disease Model.” I am not suggesting that PSSD is Alzheimer’s, that amyloid is involved, or that the same circuit is necessarily affected. What caught my attention was the actual circuit mechanism and the way the researchers treated it.
In young 5xFAD mice, cognitive inflexibility appeared before spatial-memory impairment. The mice were not simply experiencing a global loss of cognition. Instead, the researchers found abnormal neuronal reactivation in the medial prefrontal cortex and dorsomedial striatum. mPFC neurons were hyperexcitable and receiving increased excitatory input. More specifically, glutamatergic transmission from the mPFC to striatal direct-pathway medium spiny neurons was enhanced. This increased inhibitory transmission onto striatal cholinergic interneurons, which reduced their spontaneous firing and diminished striatal acetylcholine release. The result was impaired reversal learning and cognitive flexibility. (⁠nature.com)
What I found particularly interesting is that the researchers did not simply try to “increase cognition” globally or replace a supposedly missing neurotransmitter. They used sustained chemogenetic inhibition to dampen the pathological corticostriatal circuit. This reduced glutamatergic transmission, increased acetylcholine levels, attenuated cortical amyloid accumulation and rescued the reversal-learning deficit in the mice. In other words, they identified a dysregulated circuit state and targeted the abnormal circuit dynamics themselves. (⁠nature.com)
This made me rethink my own hypothesis.
When I say “the drug reduced my brain’s ability to internally connect things,” I may have initially translated that into the overly simplistic idea that my brain connections were “weakened.” But perhaps the more accurate concept is persistent maladaptive network dynamics and impaired coordination between neural systems.
My experience is that I can still technically think, but I no longer naturally enter the same states of deep thought, spontaneous associative thinking, creativity or stream of consciousness that I had before. It feels less like the individual thoughts are gone and more like they no longer naturally propagate into one another.
This is why I have been thinking about the DMN, but I am increasingly questioning whether “DMN undershoot” is too narrow as the central hypothesis. Maybe the relevant problem is not simply that one network is underactive. Maybe serotonergic antidepressants could, in susceptible individuals, induce persistent changes in network-state dynamics, plasticity and the coordination between networks, making certain internal cognitive states harder to spontaneously enter, sustain or transition into.
The Alzheimer’s study gave me a conceptual model for this: the brain can retain basic cognitive capacity while the dynamics of a circuit become abnormal enough to impair a specific function. In that study, the problem was not “the mice lost all cognition.” A pathological circuit configuration was interfering with cognitive flexibility.
I wonder whether something conceptually analogous could happen in PSSD - obviously involving completely different mechanisms and circuits - where the issue is not simply “low dopamine,” “low serotonin” or “emotional numbness,” but an abnormal network configuration that impairs the integration of internally generated thought, emotional salience, interoception and reward.
This also makes me think about treatment differently. If this type of model were relevant to PSSD, the logical treatment would perhaps not be simply to increase a neurotransmitter globally. It could involve identifying the abnormal network/circuit state and attempting to normalise its dynamics or restore the downstream neuromodulatory balance, potentially through personalised neuromodulation or other interventions that influence plasticity.
In simpler terms: maybe the problem is not that the brain has lost its cognitive content, but that it has lost its previous way of dynamically connecting and integrating that content.
I would genuinely like to know whether other people with PSSD recognise this specific experience - not simply emotional numbness, but a change in the way thoughts, feelings and internal states naturally connect and flow.

I'm turning 35 soon and thinking about fertility and freezing my eggs. I don't like to think too hard about my odds dating with PSSD, because it depresses me and I have no idea how to tell someone and am terrified of them walking away. I mostly avoid thinking about it, if I'm honest.

Pregnancy scares me, though. I took SSRIs before and through puberty. There is no research on how that impacts fetal development, not even in rats. There's research on how taking SSRIs during pregnancy impact the fetus (it frequently disrupts sexual behavior in rats), but there's nothing about what happens for someone like me.

Serotonin is critical for development--will my fetus's development be messed up developing in my disordered body? What if that looks like some kind of version of PSSD? I'm in a financial position to have a surrogate carry for me, if I want. Am I selfish if I carry the baby to term, given that unknown risk? What if developing in me with a wack maternal serotonin system means I deprive them of a sexuality, too?

But then I wonder, are my eggs contaminated? I took SSRIs through puberty. Is my entire body tainted? Am I selfish to have a child at all?

Then I collapse into grief about all the things SSRIs already stole from me, and wonder if it will steal having a healthy child from me, too.

On one hand, no studies leave the door open for the possibility nothing is wrong, and my potential children might be fine and I won't be selfish having a child. On the other hand, no studies means I don't know, and I hate gambling with my child's life the way my parents and psychiatrist did with mine.

My heart would shatter into a million pieces if my child had PSSD symptoms, too.

Anybody here that besides of sexual dysfunction, they also cannot sleep? I cannot feel sleepy even when I am tired and it’s been 4 months. The last time I had good and deep sleep was 4 months ago. Can Magnesium Glycinate aid in my sleep? I tried taking Melatonin but it didn’t help me sleep.

I find the basic premise of this diet (meat, veggies, non gluten carbs, no dairy, limit added sugar) very helpful for keeping in remission my brain fog, anhedonia, fatigue and depression/anxiety as long as you take caution not to become obsessive or rigid about it (I eat whatever’s available at a work function or other group social situation instead of going hungry for example). The AIP diet is a cousin of the carnivore, keto and paleo trends. The basic idea is eating foods that are easy to digest.

Here is a critical article just for balance on the subject.

https://www.restartmed.com/aip-diet/

KEY TAKEAWAYS

Before going on the AIP diet, clean up your existing diet first by removing added sugars, processed foods, seed oils, and artificial sweeteners. Most people improve significantly with these basics alone.
Get tested for food sensitivities (delayed IgG testing) and gluten antibodies before trying AIP, since undiagnosed sensitivities may be driving your symptoms and you don't need to restrict everything if only a few foods bother you.
AIP can inadvertently cause calorie restriction and metabolic damage, especially in people with already slow metabolisms. Consider basic gut supplements like L-glutamine and probiotics before adopting such a restrictive diet.
If you have SIBO (small intestinal bacterial overgrowth), untreated hormone imbalances, or thyroid dysfunction, the AIP diet alone won't fix these and you'll keep struggling even if you're perfectly compliant.
Only consider AIP if you have multiple autoimmune conditions, severe debilitating symptoms, or have already exhausted basic treatments like fixing thyroid function, treating SIBO, and cleaning up your diet.

In addition to this basic info page you can find many recipes online you may also lookup Mediterranean diet.

https://www.healthline.com/nutrition/aip-diet-autoimmune-protocol-diet